The Move toward Accountable Care
How Should Labs Respond to Healthcare Reform?
By Bill Malone

This year labs and other providers are getting their first glimpse of how the Affordable Care Act will affect the delivery of care. Chief among several new Medicare initiatives is the Shared Savings Program that recognizes Accountable Care Organizations. According to experts, laboratorians will have to reach out of their comfort zones and be proactive if they want to play a role in this new model of care.

Newborn Screening for Duchenne Muscular Dystrophy
New Therapies, Screening Strategy Poised to Change Practice
By Genna Rollins

Though clinicians have long-desired systematic newborn screening for Duchenne muscular dystrophy, it was hard to justify without evidence that early treatment would improve outcomes for affected babies. Now, however, promising treatments are on the horizon, and a research team recently developed an evidence-based model for newborn screening for the disease, setting the stage for widespread implementation of newborn screening for the disease.


Prostate Cancer
A Look at Current and Future Screening Biomarkers
By Bernard C. Cook, PhD, DABCC, FACB

The controversy over using PSA as a screening tool for prostate cancer was recently rekindled when a U.S. government task force recommended that healthy men avoid getting regular tests. Given its limitations, much effort has been focused over the years on alternate biomarkers to supplement, or even replace the PSA test, as a tumor detection tool.


Routine HIV Testing Still Lacking in High-Risk Groups


Regulatory Profiles
Industry Profiles
Diagnostic Profiles
News from the FDA